Evidence map›Paper›PMID 36455284›Full record

Trial reportNeurourology and urodynamics2023

Reduced versus standard intradetrusor OnabotulinumtoxinA injections for treatment of overactive bladder.

Angela M DiCarlo-Meacham, Katherine L Dengler, Eva K Welch, Daniel I Brooks, Daniel D Gruber, David J Osborn, Leah Scarlotta, Christine M Vaccaro

Open access · hybridAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Neurourology and urodynamics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Angela M DiCarlo-MeachamDepartment of Gynecologic Surgery and Obstetrics, Naval Medical Center San Diego, San Diego, California, USA.ORCID 0000-0003-1550-6672
Katherine L DenglerDepartment of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Eva K WelchDepartment of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Daniel I BrooksDepartment of Research Programs, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Daniel D GruberDepartment of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
David J OsbornDepartment of Urology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Leah ScarlottaDepartment of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Christine M VaccaroDepartment of Obstetrics and Gynecology, Walter Reed National Military Medical Center, Bethesda, Maryland, USA.
Walter Reed National Military Medical Center · USNaval Medical Center San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntradetrusor onabotulinumtoxinA injection is an effective advanced treatment for overactive bladder. While the effective dosages have been well studied, very little data exist on treatment efficacy using differing injection techniques. The objective of this study was to determine whether the efficacy of a reduced injection technique of 5 injection sites was noninferior to the standard technique of 20 injection sites of intradetrusor onabotulinumtoxinA for treatment of overactive bladder.

methodsIn this randomized noninferiority trial, men and women seeking treatment of overactive bladder with intradetrusor onabotulinumtoxinA injections were randomized to receive 100 units administered via either a reduced injection technique of 5 injection sites or a standard injection technique of 20 injection sites. Subjects completed a series of standardized questionnaires at baseline and at 4-12 weeks postprocedure to determine symptom severity and treatment efficacy. The primary outcome was treatment efficacy as determined by Overactive Bladder Questionnaire-Short Form with a noninferiority margin of 15 points. Secondary outcomes were incidence of urinary tract infection and urinary retention requiring catheterization.

resultsData from 77 subjects were available for analysis with 39 in the control arm (20 injections) and 38 in the study arm (5 injections). There was a significant improvement in both arms from baseline to follow-up in Overactive Bladder Questionnaire-Short Form and International Consultation on Incontinence Questionnaire scores (p < 0.001). Overall treatment success was 68% with no statistically significant difference between arms. A significant difference between arms was found on the Overactive Bladder Questionnaire-Short Form quality of life survey favoring the control arm (confidence interval [CI]: 0.36-20.5, p = 0.04). However, there were no significant differences between arms in the remaining validated questionnaires. The study arm did not demonstrate noninferiority to the control arm. Subjects in the study arm were significantly more likely to express a willingness to undergo the procedure again (odds ratio = 3.8, 95% CI: 1.42-10.67, p = 0.004). Adverse events did not differ between arms.

conclusionsA reduced injection technique for administration of intradetrusor onabotulinumtoxinA demonstrates similar efficacy to the standard injection technique but did not demonstrate noninferiority. Subjects preferred the reduced injection technique over the standard technique. A reduced injection technique is a safe and effective alternative to the standard technique.

Indexed as

Botulinum Toxins, Type AUrinary Bladder, OveractiveUrinary IncontinenceFemaleHumansInjections, IntramuscularMaleQuality of LifeTreatment OutcomeBotulinum Toxins, Type Adetrusor overactivitynocturiapatient-centered outcomesquality of lifeurinary frequencyurinary incontinenceurinary urgency

Identifiers

PMID36455284
PMCPMC10108158
OpenAlexW4310516639

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.